. 2021 Jul 26;111(1):200–208. doi: 10.1002/cpt.2362

Table 2.

Incidence rates by 1,000 person‐years in both cohorts as well as crude and adjusted HRs and 95% CI) for risk of cancer in VKA patients compared to DOAC patients

Cancer	Group	Person‐time	Failures	Rate	95% CI		Crude HR	95% CI		Adj. HR	95% CI
Any	DOAC	23,051.44	287	12.45	11.09	13.98	1.19	1.05	1.35	1.16	1.02	1.32
	VKA	91,751.50	1335	14.55	13.79	15.35	1.19	1.05	1.35	1.16	1.02	1.32
Lung	DOAC	23,493.70	36	1.53	1.11	2.12	1.31	0.92	1.87	1.28	0.89	1.83
	VKA	93,846.79	185	1.97	1.71	2.28	1.31	0.92	1.87	1.28	0.89	1.83
Colon	DOAC	23,452.44	56	2.39	1.84	3.10	0.88	0.65	1.19	0.84	0.62	1.13
	VKA	93,789.97	192	2.05	1.78	2.36	0.88	0.65	1.19	0.84	0.62	1.13
Prostate	DOAC	12,423.58	29	2.33	1.62	3.36	1.34	0.90	1.99	1.40	0.94	2.10
	VKA	48,502.67	152	3.13	2.67	3.67	1.34	0.90	1.99	1.40	0.94	2.10
Bladder	DOAC	23,480.53	40	1.70	1.25	2.32	1.10	0.78	1.56	1.07	0.76	1.52
	VKA	93,815.44	172	1.83	1.58	2.13	1.10	0.78	1.56	1.07	0.76	1.52
Breast	DOAC	11,054.97	22	1.99	1.31	3.02	1.06	0.67	1.68	1.05	0.66	1.69
	VKA	45,197.77	95	2.10	1.72	2.57	1.06	0.67	1.68	1.05	0.66	1.69

Adj, adjusted; CI, confidence interval; DOAC, direct oral anticoagulant; HR, hazard ratio; VKA, vitamin K antagonist.

HR reference group: DOAC cohort.